glp-1 and vertigo The Risk of Vestibular Disorders with Semaglutide Tirzepatide: Findings from a Large Real-World Cohort GLP-1 and health: Beyond weight

Blood pressure and heart rate monitoring Cardiovascular monitoring remains paramount for GLP-1 non-responders transitioning to sympathomimetic agents like phentermine

Wegovy (semaglutide) is a once-weekly injectable medication licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Yoshida Y, et al

Average of 12.4% of body weight lost Participants taking the highest dose of Foundayo who completed the full treatment period lost an average of 27.3 pounds about 12.4% of their body weight compared to just 2.2 pounds in the placebo group

Frequently asked questions I was denied for Wegovy by Medicare last year